A biquinoline / bipyridine ruthenium complex and its preparation method and application

CN115850348BActive Publication Date: 2024-12-03NANTONG UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202310012882.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-01-05
Publication Date
2024-12-03
Estimated Expiration
2043-01-05

AI Technical Summary

Technical Problem

The existing metal complex photosensitizers have problems such as poor stability and insufficient therapeutic activity in photodynamic therapy, and chemotherapy is prone to drug resistance and poor treatment selectivity.

Method used

Using bipyridine as the parent nucleus, a novel biquinoline/bipyridine-based ruthenium complex was prepared by introducing different hydrophilic nitrogen-containing saturated heterocyclic rings and ruthenium metal precursors, and their spectral characteristics and photo-chemotherapeutic activity were studied, combining light. Synergistic effects of dynamics and chemotherapy.

Benefits of technology

It has achieved significant photodynamic and chemotherapy effects on a variety of tumor cells, with near-infrared fluorescence characteristics, large Stokes displacement, low tissue background fluorescence interference, good light stability and high singlet oxygen quantum yield, which can be effective Kill tumor cells and are used for the treatment of malignant tumors and fluorescence imaging.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115850348B_ABST
    Figure CN115850348B_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of drug preparation, and discloses a biquinoline / bipyridine ruthenium complex and a preparation method and application thereof. The biquinoline / bipyridine ruthenium complex has a structure shown in general formula I: wherein R is selected from the biquinoline / bipyridine ruthenium complex. The biquinoline / bipyridine ruthenium complex not only has mitochondrial targeted fluorescence imaging, but also has a certain cytotoxic therapeutic effect. After being exposed to light, it can generate a high concentration of reactive oxygen, which can further kill tumor cells and has an excellent photo-chemical synergistic therapeutic effect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of drug preparation, and relates to a biquinoline / bipyridine ruthenium complex and a preparation method and application thereof, and in particular to a biquinoline / bipyridine ruthenium complex having a photo-chemotherapeutic effect and a pharmaceutically acceptable salt thereof, their preparation method and their medical use, in particular their application in the preparation of drugs for photo-chemotherapy of malignant tumors. Background Art

[0002] Photodynamic therapy, as a new type of therapy different from traditional cancer treatments, has received widespread attention from scientific researchers in recent years. Photodynamic therapy uses a specific wavelength to irradiate the tumor site, activating photosensitizers that selectively accumulate in the tumor site. The photosensitizer then transfers energy to the surrounding oxygen to generate reactive oxygen species. The reactive oxygen species react with the surrounding biomacromolecules to produce oxidative stress and cytotoxicity, thereby killing tumor cells. Compared with traditional therapies, photodynamic therapy is not limited by radiotherapy or chemical resistance. It has broad prospects in tumor treatment due to its incomparable advantages such as low trauma, low toxic side effects, good applicability, and repeatable treatment.

[0003] As the core component of photodynamic therapy, the development and selection of photosensitizers play a key role in the effect of photodynamic therapy. Therefore, the research on photosensitizers has attracted widespread attention from many scientific researchers. Metal complexes are an important research direction for the development of new photosensitizers. Although metal complex photosensitizers based on Pt(II), Pt(IV), Ru(II), etc. have been reported, this type of photosensitizer still has defects such as poor stability and insufficient photodynamic therapy activity. Further research and development of new metal complex photosensitizers is needed to solve these problems.

[0004] Chemotherapy is one of the main means of treating cancer at present, but chemotherapy is also prone to certain drug resistance and poor treatment selectivity. If photodynamic therapy can be effectively combined with chemotherapy, it can effectively improve the tumor treatment effect, reduce toxic side effects, and induce the body to produce a long-term anti-tumor immune response to achieve a maximized therapeutic effect. Therefore, the present invention uses bipyridine as the parent nucleus to synthesize a new nitrogen ligand, and then combines a ruthenium metal precursor (multidentate nitrogen biquinoline-ruthenium complex) to prepare a new and functional ruthenium complex, and studies its spectral characteristics and photodynamic anti-tumor activity. The study found that this type of complex has a strong photodynamic therapy and chemotherapy effect on a variety of tumor cells (including colon cancer, breast cancer, lung cancer and cervical cancer, etc.). Therefore, the present invention discloses a type of biquinoline / bipyridine type novel ruthenium complex with photo-chemotherapeutic effect and a pharmaceutically acceptable salt thereof, and there is no report on this type of complex. Summary of the invention

[0005] In view of this, the object of the present invention is to provide a biquinoline / bipyridine ruthenium complex and its preparation method and application. The biquinoline / bipyridine ruthenium complex and its pharmaceutically acceptable salt have photo-chemotherapeutic effects and can be used in the preparation of malignant tumor therapeutic drugs or near-infrared fluorescence imaging agents.

[0006] The technical solution of the present invention is:

[0007] A biquinoline / bipyridine ruthenium complex having the following general formula I:

[0008]

[0009] Among them, R is selected from One of them.

[0010] Preferably, R is The present invention also provides a method for preparing the above-mentioned biquinoline / bipyridine ruthenium complex, and the synthesis route is as follows:

[0011]

[0012] R is selected from One of;

[0013] The steps include:

[0014] S1. First, the methyl group at the 4'-position of compound 1 is oxidized to an aldehyde group by selenium dioxide to obtain compound 2, and then compound 2 is directly reduced by sodium borohydride to obtain compound 3, and compound 3 is then substituted with phosphorus tribromide to obtain compound 4, and compound 4 is reacted with various nitrogen heterocycles to obtain compound 5;

[0015] S2. Compound 6 undergoes coordination reaction with hydrated ruthenium trichloride to obtain compound 7;

[0016] S3. Compound 5 and compound 7 undergo coordination reaction in a mixed solution of water and methanol containing ammonium hexafluorophosphate to generate biquinoline / bipyridine ruthenium complex I;

[0017] The present invention also provides the use of the biquinoline / bipyridine ruthenium complex in preparing medicine for treating malignant tumors.

[0018] Furthermore, the drug for treating malignant tumors is a drug for photodynamic therapy and chemotherapy of malignant tumors.

[0019] Furthermore, the malignant tumor is breast cancer, colon cancer, lung cancer or cervical cancer.

[0020] The present invention also provides the use of the biquinoline / bipyridine ruthenium complex in preparing a near-infrared fluorescence imaging agent with mitochondrial targeting co-localization.

[0021] Compared with the prior art, the present invention uses bipyridine as the parent nucleus, introduces a nitrogen-containing saturated heterocycle with different hydrophilicity into the methyl group at the 4' position of 4,4'-dimethyl-2,2'-bipyridine, and then combines biquinoline and a ruthenium metal precursor (multidentate nitrogen-ruthenium complex) to prepare a novel and functional biquinoline / bipyridine ruthenium complex. Currently, no reports on such complexes have been found. In addition, the present invention also studies the spectral characteristics and photo-chemotherapeutic tumor activity of the biquinoline / bipyridine ruthenium complex, and finds that the complex has near-infrared fluorescence characteristics, large Stokes shift, low tissue background fluorescence interference, good photostability and singlet oxygen ( 1 O2) has the advantages of high quantum yield, which not only realizes fluorescence imaging of tumor cells, but also has significant synergistic therapeutic effects of chemotherapy and photodynamic therapy on various tumor cells (including breast cancer, lung cancer, etc.), and can effectively kill tumor cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 The ultraviolet absorption spectra of the biquinoline / bipyridine ruthenium complexes obtained in Examples 5 and 6 of the present invention;

[0023] Figure 2 The fluorescence emission spectra of the biquinoline / bipyridine ruthenium complexes obtained in Examples 5 and 6 of the present invention;

[0024] Figure 3 This is a graph showing the fluorescence imaging results of the biquinoline / bipyridine ruthenium complex I2 obtained in Example 6 of the present invention in A549 cells. DETAILED DESCRIPTION

[0025] In order to further illustrate the present invention, a series of examples are given below. These examples are purely illustrative and are only used to specifically describe the present invention, and should not be understood as limiting the present invention.

[0026] Example 1 Preparation of 4-methyl-2,2'-bipyridine-4'-carboxaldehyde (Compound 2)

[0027] 4,4'-Dimethyl-2,2'-bipyridine (10mmol, 1.84g) and SeO2 (15mmol, 0.56g) were dissolved in 1,4-dioxane (25mL), and the mixture was heated under nitrogen protection and refluxed at 110°C for 24h. The reaction was monitored by thin layer chromatography to see if it was complete. After the reaction was completed, the mixture was cooled to room temperature, the solvent was removed by vacuum vortexing, and the crude product was purified by column chromatography (ammonia MeOH: DCM = 1:25) to obtain compound 2 (1.247g) as a white solid with a yield of 63%.

[0028] 1 H NMR (400MHz, CDCl3) δ10.18(s,1H,CH=O),8.40(d,J=5.1Hz,2H,2ArH),7.85(dd,J=5.0,1.6Hz,2H,2ArH),7.72(dd,J=4.9,1.6Hz,2H,2ArH),2.04(s,3H,CH3). 13 C NMR (101MHz, CDCl3) δ192.51,160.74,150.32,149.79,149.21,143.30,142.63,125.42,122.11,121.39,120.62,21.22.

[0029] Example 2 Preparation of 4-methyl-2,2'-bipyridine-4'-methanol (Compound 3)

[0030] Compound 2 (8 mmol, 1.585 g) was dissolved in CH3CH2OH (20 mL), stirred for 5 min, and then NaBH4 (16 mmol, 0.605 g) was added, and the mixture was stirred for 1 h. The reaction was monitored by thin layer chromatography to determine whether it was complete. After the reaction was complete, 1 to 2 drops of water were added to quench the reaction, and then the solvent was dried under reduced pressure, and saturated brine (30 mL) was added, and the mixture was extracted with DCM (20 mL×3). The organic layer was dried over anhydrous Na2SO4, and the solvent was removed under reduced pressure to obtain compound 3 (1.361 g) as a light yellow solid, with a yield of 86%.

[0031] 1 H NMR (400MHz, CDCl3) δ8.52(m,2H,2ArH),8.28(s,1H,ArH),8.17(s,1H,ArH),7.20( dd,J=52.7,5.0Hz,2H,2ArH),4.75(s,2H,CH2),4.02(s,1H,OH),2.42(s,3H,CH3). 13 CNMR(101MHz, CDCl3)δ155.97,155.75,151.70,149.14,148.73,148.59,124.86,122.37,121.19,118.73,63.26,21.22.

[0032] Example 3 Preparation of 4-methyl-2,2'-bipyridine-4'-bromomethyl (Compound 4)

[0033] Compound 3 (6mmol, 1.2g) was dissolved in DCM (20mL), stirred in an ice bath for 5min, and then PBr3 (6mmol, 1.624g) was slowly added dropwise. After stirring for 10min, the reaction solution temperature was restored to room temperature, and then stirred for 10h. The reaction was monitored by thin layer chromatography to see if it was complete. After the reaction was completed, the pH was adjusted to 7 with 2mol / L NaHCO3 solution, and then extracted with DCM (20mL×3). The organic layer was dried with anhydrous Na2SO4 and the solvent was removed under reduced pressure to obtain compound 4 (1.258g) as a light yellow solid with a yield of 87%.

[0034] 1 H NMR (400MHz, CDCl3) δ8.57(d,J=4.9Hz,1H,ArH),8.46(d,J=4.9Hz,1H,ArH),8.33(d,J=1.8Hz,1H,ArH),8.19– 8.13(m,1H,ArH),7.29–7.23(m,1H,ArH),7.07(dd,J=5.1,1.7Hz,1H,ArH),4.40(s,2H,CH2),2.36(s,3H,CH3). 13 C NMR (101MHz, CDCl3) δ156.9,155.3,149.6,149.0,148.2,147.1,125.0,123.5,122.0,120.9,30.7,21.2.

[0035] Example 4 Preparation of Bisquinoline Ruthenium Dichloride (Compound 7)

[0036] 2,2'-Biquinoline (6mmol, 1.536g), LiCl (3mmol, 0.127g) and hydrated ruthenium trichloride (3mmol, 0.622g) were dissolved in anhydrous DMF (25ml) and heated to reflux at 165℃ for 8h. The reaction was monitored by thin layer chromatography to see if it was complete. After the reaction was completed, it was cooled to room temperature, 150ml of acetone was added to the reaction solution, and then placed at 0℃ overnight. The solution was filtered out using filter paper, leaving the solid, which was washed with water (5mL×3) and chloroform (10mL×3). The solid was vacuum dried and then purified by column chromatography (ammonia MeOH: DCM=1:20) to obtain compound 7 (1.108g) as a green solid with a yield of 54%.

[0037] 1H NMR (400MHz, DMSO-d6) δ8.72(dd,J=8.2,1.2Hz,8H,8ArH),8.26–8.19(m,8H,8ArH),8.14(d,J=8.9Hz,4H,4ArH),7.69(d,J=5.4Hz,4H,4ArH).

[0038] Example 5 Preparation of 4-methyl-2,2'-bipyridine-4'-((4-piperidinone)-N-methylene)-bis(2,2'-biquinolinyl)ruthenium di(hexafluorophosphate) salt (I1)

[0039] Step 1: Preparation of 4-methyl-2,2'-bipyridine-4'-((4-piperidinone)-N-methylene) (Compound 5a)

[0040] Compound 4 (4mmol, 1.048g), 4-piperidone (4mmol, 0.396g) and K2CO3 (4mmol, 0.553g) were dissolved in MeCN (20mL), stirred for 5min, and then 1-2 drops of DMF were added dropwise. The mixture was refluxed at 85℃ for 12h under nitrogen protection. The reaction was monitored by thin layer chromatography. After the reaction was completed, saturated brine (20mL) was added, and then extracted with DCM (20mL×3). The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by column chromatography (ammonia MeOH: DCM = 1:15) to obtain the target compound 5a (0.865g) as a light yellow solid with a yield of 77%.

[0041] 1 H NMR (400MHz, CDCl3) δ8.57(d,J=5.0Hz,1H,ArH),8.47(d,J=5.0Hz,1H,ArH),8.30(d,J=1.6Hz,1H,ArH),8.17(d,J=1.7Hz,1H,ArH),7.31 (dd,J=4.9,1.7Hz,1H,ArH),7.08(dd,J=5.0,1.7Hz,1H,ArH),3.64(s,2H,CH2),2.72(m,4H,2CH2),2.42(m,4H,2CH2),2.37(s,3H,CH3). 13 C NMR(CDCl3,101MHz)δ207.7,155.5,154.7,148.3,147.9,147.5,147.2,123.8,122.5,121.0,120.1,59.9,52.1,40.2,20.1.HRMS(ESI)m / z calcd forC 17 H 19 N3O[M+H]+ ,282.1606;found,282.1610.

[0042] Step 2: Preparation of 4-methyl-2,2'-bipyridyl-4'-((4-piperidinone)-N-methylene)-bis(2,2'-biquinolinyl)ruthenium di(hexafluorophosphate) salt (I1)

[0043] Compound 7 (0.5mmol, 0.342g) and compound 5a (0.5mmol, 0.140g) were dissolved in MeOH / H2O (6mL, v / v=1 / 2) and heated to reflux at 95°C for 4.5h. The reaction was monitored by thin layer chromatography to see if it was complete. After the reaction was completed, the mixture was cooled to room temperature, and ammonium hexafluorophosphate (2mmol, 0.326g) was added to the reaction solution and stirred for 10min. After the stirring was completed, the solution was filtered out using filter paper to leave the solid. The solid was washed with triple distilled water (5mL×3) and chloroform (10mL×3), and then the solid was vacuum dried. The crude product was purified by column chromatography (ammonia MeOH:DCM=1:20) to obtain the target compound I1 (0.379g) as a purple-black solid with a yield of 64%.

[0044] 1 H NMR (400MHz, DMSO-d6) δ9.36(d,J=8.6Hz,2H,2ArH),9.17(m,4H,4ArH),8.72(s,2H,2ArH),8.25(d,J=8.1Hz,2H,2ArH),8.05–7.80(m, 6H,6ArH),7.63–7.39(m,6H,6ArH),7.27(m,2H,2ArH),7.19–6.92(m,6H,6ArH),3.73–3.52(m,2H,CH2),2.33(d,J=20.6Hz,8H,4CH2). 13 C NMR(101MHz,DMSO-d6)δ208.2,161.5,161.4,161.0,160.9,156.1,155.6,151 .6,151.5,151.3,151.2,149.8,140.7,139.4,139.2,133.0,131.0,130.3,12 9.7,129.5,129.3,129.2,128.8,128.4,127.8,126.0,125.9,125.0,123.9,1 23.1,122.8,122.2,122.1,60.2,58.6,52.2,21.2,20.7,14.5.HRMS(ESI)m / z calcd forC 53 H 43 N7ORu[M+H]+ ,896.2651;found,896.2648.

[0045] Example 6 Preparation of 4-methyl-2,2'-bipyridine-4'-((N-benzylpiperazine)-N-methylene)-bis(2,2'-biquinolinyl)ruthenium di(hexafluorophosphate) salt (I2)

[0046] Step 1: Preparation of 4-methyl-2,2'-bipyridine-4'-((N-benzylpiperazine)-N-methylene) (Compound 5b)

[0047] Referring to the method described for compound 5a, N-benzylpiperazine was used instead of 4-piperidone to react with compound 4 to obtain compound 5b (1.060 g, 74%) as a yellow solid.

[0048] 1 H NMR (400MHz, CDCl3) δ8.60(d,J=5.0Hz,1H,ArH),8.54(d,J=5.0Hz,1H,ArH),8.30(d,J=1.6Hz,1H,ArH),8.22(d,J=1.7Hz,1H,ArH),7.3 6–7.31(m,4H,4ArH),7.25(m,2H,2ArH),7.13(dd,J=5.0,1.7Hz,1H,ArH),3.59(s,2H,CH2),3.54(s,2H,CH2),2.48(m,11H,CH3,4CH2). 13 C NMR (101MHz, CDCl3) δ156.2,155.9,149.1,148.9,148.6,148.1,137.7,129.3,129.0,128.3, 128.2,127.3,127.1,124.7,123.9,122.0,121.5,62.9,61.8,53.0,52.9,21.2.HRMS(ESI)m / z calcd for C 23 H 26 N4[M+H] + ,359.2236;found,359.2237.

[0049] Step 2: Preparation of 4-methyl-2,2'-bipyridyl-4'-((N-benzylpiperazine)-N-methylene)-bis(2,2'-biquinolinyl)ruthenium di(hexafluorophosphate) salt (I2)

[0050] Referring to the method described for compound I1, compound 5b was used instead of compound 5a to react with compound 7 to obtain compound I2 (0.429 g, 68%) as a purple-black solid.

[0051] 1 H NMR(400MHz,DMSO-d6)δ9.36(d,J=9.0Hz,2H,2ArH),9.23–9.11(m,4H,4ArH),8.71(m,2H, 2ArH),8.25(d,J=8.2Hz,2H,2ArH),7.96(m,3H,3ArH),7.84(dd,J=13.9,10.5Hz,3H,3ArH ),7.55(m,2H,2ArH),7.48(m,2H,2ArH),7.45–7.39(m,3H,3ArH),7.38–7.31(m,3H,3ArH) ,7.27(m,3H,3ArH),7.14(m,3H,3ArH),7.01(m,3H,3ArH),2.27(d,J=29.5Hz,10H,5CH2). 13 C NMR(101MHz,DMSO-d6)δ161.5,161.0,160.9,155.6,151.6,151.4,151.3,151.1,150.9,149.8,149.8,140.7,139.3,139.2,132.9,1 31.0,130.3,129.7,129.5,129.3,129.2,128.7,128.4,126.0,125.9,124.9,123.8,123.1,122.2,122.1,55.3,20.7.HRMS(ESI)m / z calcd for C 59 H 50 N8Ru[M+H] + ,973.3280;found,973.3276.

[0052] Test Example 1 Measurement of the UV absorption and fluorescence emission spectra of the biquinoline / bipyridine ruthenium complex of the present invention

[0053] (1) UV absorption spectra of novel biquinoline / bipyridine ruthenium complexes

[0054] Using methanol as solvent, the biquinoline / bipyridine ruthenium complexes (I1 and I2) obtained in Examples 5 and 6 were prepared into 10 μM sample solutions, and recorded using a UV-visible spectrophotometer. The temperature when recording the UV absorption spectrum was room temperature, the wavelength range of the scanning absorption spectrum was 200-800 nm, and the scanning speed was 1.0 nm / s, and the following was obtained: Figure 1 The UV absorption spectrum of the biquinoline / bipyridine ruthenium complex in methanol solution is shown in Figure 2. Figure 1It can be found that the absorption spectrum of the biquinoline / bipyridine ruthenium complex of the present invention has a very strong absorption peak in the range of 500-600nm, which may be caused by the dπ-π* electronic transition (MLCT) between the metal Ru and the ligand biq.

[0055] (2) Fluorescence emission spectra of novel biquinoline / bipyridine ruthenium complexes

[0056] Using methanol as solvent, the biquinoline / bipyridine ruthenium complexes (I1 and I2) obtained in Examples 5 and 6 were prepared into 10 μM sample solutions, and the fluorescence emission spectra of the ruthenium complexes were recorded using a fluorescence spectrophotometer with an excitation wavelength of 452 nm. The temperature when recording the emission spectrum was room temperature, and the wavelength range of the emission spectrum was 470-900 nm, and the scanning speed was 1.0 nm / s. Figure 2 As shown, the fluorescence emission spectra of the biquinoline / bipyridine ruthenium complexes of the present invention have a maximum corresponding wavelength in the range of 700-800 nm, and the wavelength of the fluorescence reaches the near-infrared range.

[0057] Test Example 2 Determination of Singlet Oxygen Quantum Yield of Biquinoline / Bipyridine Ruthenium Complexes

[0058] DPBF was selected as the singlet oxygen scavenger, and methanol was selected as the solvent. In methanol, the absorbance of DPBF at 412 nm was adjusted to about 1.0; then, in order to reduce the singlet oxygen quenching of the control and the complex to be tested, I1, I2 and the control [Ru(bpy)3] 2+ The absorbance values ​​at 520 nm were adjusted to below 0.1. Then, the transparent side of the quartz cell was exposed to a laser (40 mW) with a wavelength of 520 nm for a total of 5 minutes. The absorption spectrum was recorded at different time periods during the 5 minutes. The scanning wavelength range was 300-600 nm, and the scanning speed was 1.0 nm / s.

[0059] With the known singlet oxygen quantum yield of [Ru(bpy)3] 2+ As a standard, the singlet oxygen quantum yield was calculated by the following formula:

[0060] Φ T =Φ X (S T F X / SxF T )

[0061] Φ: singlet oxygen quantum yield; S: the slope of the straight line with irradiation time as x-axis and the UV absorbance of DPBF at 412nm after the corresponding irradiation time as y-axis; F: absorption correction factor of unknown sample and reference standard, F = 1-10 -OD OD represents the ultraviolet absorption value of the compound under the irradiation wavelength; X and T represent the reference standard and the unknown sample, respectively. The results are shown in Table 1. We found from Table 1 that most of the biquinoline / bipyridine ruthenium complexes of the present invention have a high singlet oxygen quantum yield.

[0062] Table 1 Singlet oxygen quantum yield of biquinoline / bipyridine ruthenium complexes of the present invention

[0063]

[0064] Test Example 3: Study on the tumor cell proliferation inhibition rate of the biquinoline / bipyridine ruthenium complex of the present invention by using the MTT method

[0065] MTT was routinely used to evaluate the cytotoxicity of the biquinoline / bipyridine ruthenium complex of the present invention to human colon cancer cells HT29, human breast cancer cells MCF-7, human lung adenocarcinoma cells A549, and human cervical cancer cells Hela under dark conditions and after irradiation with light of a specific wavelength. The MTT method has been widely used in large-scale anti-tumor drug screening, cytotoxicity tests, etc. 2+ As a positive control drug.

[0066] The experimental method is as follows: Take a bottle of cells in good exponential growth phase, add 0.25% trypsin to digest, so that the attached cells fall off, and make a mixture containing 2×10 4 ~4×10 4 The cell suspension was inoculated on a 96-well plate, 180 μL per well, and cultured in a constant temperature CO2 incubator for 24 hours. The medium was changed and the test compounds I1 and I2 and the positive control drug [Ru(bpy)3] were added. 2+ (The compounds were dissolved in DMSO and then diluted with PBS. The concentrations of the tested compounds were 12.5×10 -6 mol / L), 20μL was added to each well, the Dark group was directly cultured for 24 hours, the Light group was incubated for 2h, illuminated with 520nm excitation light for 10min, and then continued to culture for 22 hours. MTT was added to a 96-well plate, 20μL per well, and reacted in an incubator for 4h. The supernatant was aspirated, DMSO was added, 150μL per well, and shaken on a plate shaker for 5 minutes. The absorbance of each well was measured at a wavelength of 570nm using an enzyme-linked immunosorbent assay, and the cell inhibition rate was calculated. The experimental results are shown in Table 2.

[0067] Cell inhibition rate = (OD value of negative control group - OD value of test substance group) / OD value of negative control group × 100%.

[0068] The biquinoline / bipyridine ruthenium complexes of the present invention were tested for anti-proliferative activity on tumor cells. The pharmacological experimental results showed (see Table 2) that under dark conditions, the biquinoline / bipyridine ruthenium complexes I1 and I2 of the present invention had certain anti-tumor activity on tumor cells at a concentration of 10 μM, while the wavelength was 520 nm (200 mW / cm -2 ) after 10 min of LED light irradiation, it showed significantly enhanced tumor cell toxicity, which was significantly stronger than the positive control drug [Ru(bpy)3] 2+ This indicates that the compound of the present invention not only has a photodynamic therapy effect, but also has a chemotherapeutic effect, a photo-chemotherapeutic effect, and exerts a synergistic and significant anti-cancer effect.

[0069] Table 2 Survival rate of some compounds of the present invention on human cancer cells (12.5 μM)

[0070]

[0071] ND: Not tested.

[0072] Test Example 4: Cell fluorescence imaging experiment using confocal microscope

[0073] Confocal microscopy was used to perform cell fluorescence imaging and mitochondrial localization experiments. Human lung cancer cells A549 were cultured in a laser confocal dish with DEME culture medium for 12 to 24 hours, and 5 to 20 μM of the test compound I2 was added. The cells were placed in a cell culture incubator at 37°C and 5% CO2 for half an hour. Then, the cells were washed three times with a pH = 7.4 phosphate buffer solution, and then 1 μM of the mitochondrial dye MitoTracker red solution was added and incubated for another half an hour, and then washed three times with a pH = 7.4 phosphate buffer solution. The incubated cells were placed on the stage of a confocal microscope for confocal fluorescence imaging, and the excitation wavelength of the test compound was set to: λex = 500-580nm, and the emission wavelength λem = 700-800nm.

[0074] like Figure 3 As shown, the results indicate that the compound I2 of the present invention can clearly image the fluorescence of tumor cells and overlaps well with the fluorescence imaging of mitochondrial probes, which indicates that the compound of the present invention can target and localize in mitochondria in tumor cells.

Claims

1. A biquinoline / bipyridine ruthenium complex, It is characterized in that The biquinoline / bipyridine ruthenium complex has a structure shown in general formula I: Among them, R is selected from One of them.

2. The biquinoline / bipyridine ruthenium complex according to claim 1, It is characterized in that R is 3. The method for preparing the biquinoline / bipyridine ruthenium complex according to claim 1, It is characterized in that The synthetic route of the preparation method is as follows: Among them, R is selected from One of; The preparation method comprises the following steps: S1. The methyl group at the 4'-position of compound 1 is oxidized to an aldehyde group by selenium dioxide to obtain compound 2, and then compound 2 is directly reduced by sodium borohydride to obtain compound 3, and compound 3 is then substituted with phosphorus tribromide to obtain compound 4, and compound 4 is reacted with various nitrogen heterocycles to obtain compound 5; S2. Compound 6 undergoes coordination reaction with hydrated ruthenium trichloride to obtain compound 7; S3. Compound 5 and compound 7 undergo coordination reaction in a mixed solution of water and methanol to generate biquinoline / bipyridine ruthenium complex I.

4. Use of the biquinoline / bipyridine ruthenium complex according to claim 1 or 2 in the preparation of a drug for treating a malignant tumor, wherein the malignant tumor is one of breast cancer, colon cancer, cervical cancer and lung cancer.

5. The use according to claim 4, It is characterized in that The medicine for treating malignant tumors is a medicine for photodynamic therapy and chemotherapy of malignant tumors.

6. Use of the biquinoline / bipyridine ruthenium complex according to claim 1 or 2 in the preparation of a near-infrared fluorescence imaging agent with mitochondrial targeted co-localization.

Citation Information

Patent Citations

  • Beta-carboline pyridinium salt fluorescent probe as well as preparation method and application thereof

    CN111875603A

  • Arene Ruthenium Complex, Preparation Method and Utilization Thereof

    US20180334473A1